Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

Jinghua Duan, Heidi - Mansour, Yangde Zhang, Xingming Deng, Yuxiang Chen, Jiwei Wang, Yifeng Pan, Jinfeng Zhao

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume426
Issue number1-2
DOIs
StatePublished - Apr 15 2012
Externally publishedYes

Fingerprint

Cyanoacrylates
Curcumin
Chitosan
Multiple Drug Resistance
Nanoparticles
Doxorubicin
Polymerization
Cell Line
MCF-7 Cells
P-Glycoprotein
Drug Combinations
Emulsions
Particle Size
Pharmaceutical Preparations
Breast
Down-Regulation
Western Blotting

Keywords

  • Curcumin
  • Doxorubicin
  • Multidrug resistance
  • Poly(butyl cyanoacrylate) nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. / Duan, Jinghua; Mansour, Heidi -; Zhang, Yangde; Deng, Xingming; Chen, Yuxiang; Wang, Jiwei; Pan, Yifeng; Zhao, Jinfeng.

In: International Journal of Pharmaceutics, Vol. 426, No. 1-2, 15.04.2012, p. 193-201.

Research output: Contribution to journalArticle

Duan, Jinghua ; Mansour, Heidi - ; Zhang, Yangde ; Deng, Xingming ; Chen, Yuxiang ; Wang, Jiwei ; Pan, Yifeng ; Zhao, Jinfeng. / Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. In: International Journal of Pharmaceutics. 2012 ; Vol. 426, No. 1-2. pp. 193-201.
@article{0ae34463155946c1bd8ce8e7fa12b40b,
title = "Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles",
abstract = "Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32{\%} and 94.52 ± 3.14{\%}, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.",
keywords = "Curcumin, Doxorubicin, Multidrug resistance, Poly(butyl cyanoacrylate) nanoparticles",
author = "Jinghua Duan and Mansour, {Heidi -} and Yangde Zhang and Xingming Deng and Yuxiang Chen and Jiwei Wang and Yifeng Pan and Jinfeng Zhao",
year = "2012",
month = "4",
day = "15",
doi = "10.1016/j.ijpharm.2012.01.020",
language = "English (US)",
volume = "426",
pages = "193--201",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

AU - Duan, Jinghua

AU - Mansour, Heidi -

AU - Zhang, Yangde

AU - Deng, Xingming

AU - Chen, Yuxiang

AU - Wang, Jiwei

AU - Pan, Yifeng

AU - Zhao, Jinfeng

PY - 2012/4/15

Y1 - 2012/4/15

N2 - Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.

AB - Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The mean particle size and mean zeta potential of CUR-DOX-PBCA-NPs were 133 ± 5.34 nm in diameter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2- yl] 2,5-diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs (DOX-PBCA-NPs + CUR-PBCA-NPs), which was slightly higher than that of the free drug combination (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR-PBCA-NPs or CUR + DOX-PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced by combination delivery of encapsulated cytotoxic drugs and reversal agents.

KW - Curcumin

KW - Doxorubicin

KW - Multidrug resistance

KW - Poly(butyl cyanoacrylate) nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84862808031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862808031&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2012.01.020

DO - 10.1016/j.ijpharm.2012.01.020

M3 - Article

C2 - 22274587

AN - SCOPUS:84862808031

VL - 426

SP - 193

EP - 201

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -